Efficacy and Safety of Hospital-Based Intravenous Immunoglobulin and Home-Based Self-Administered Subcutaneous Immunoglobulin in Polish Children with Primary Immunodeficiency Diseases

Bal, K.; Kałuzińska-Parzyszek, Izabela; Sobocińska, Agnieszka; Podlecka, Daniela; Jerzyńska, Joanna; Stelmach, Iwona

doi:10.1007/s12098-015-1731-5

Cited by 3 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, our cohort did not include hospitalized patients who are typically older, less healthy, and have multiple comorbidities; all of these factors increase the likelihood of adverse effects occurring. Similar results confirming the efficacy, safety, and improved quality of life outcomes in patients with primary immune deficiency receiving home‐based intravenous and subcutaneous immunoglobulin have been reported; however, the IVIg dose used is typically lower in immune deficiency states than in neuromuscular disorders . Third, the lower AE rate could be the result of a shorter follow‐up period in our study.…”

Section: Discussionsupporting

confidence: 89%

Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease

Waheed

Ayer²,

Jadoo³

et al. 2019

Muscle and Nerve

View full text Add to dashboard Cite

Introduction Although intravenous immune globulin (IVIg) is used to treat patients in the outpatient setting, there is limited documentation addressing the safety of this practice. Methods Retrospective analysis of 438 patients with neuromuscular diseases receiving IVIg in an outpatient setting. Results Adverse events (AE) overall occurred in 16.9% of patients. Headache was the most common AE, noted in 11.6% of patients. Serious AEs occurred in 0.91% of patients; aseptic meningitis was the only one noted. Multivariate analyses identified the following risk factors for AEs: first‐lifetime course of IVIg, higher dose per course of IVIg, diagnosis of myasthenia gravis, women, and younger age. Discussion Intravenous immune globulin is generally safe to administer in an outpatient setting. Women, myasthenia gravis patients, and those receiving their first course or a higher total dose of IVIg are at an increased risk of experiencing an AE.

show abstract

Section: Discussionsupporting

confidence: 89%

Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease

Waheed

Ayer²,

Jadoo³

et al. 2019

Muscle and Nerve

View full text Add to dashboard Cite

show abstract

“…Several clinical trials of subcutaneously administered infusions of immunoglobulin, formulated for intramuscular use, provided high serum levels for IgG and comparable protection from infection, while adverse events were reduced when compared to IVIg. 6,[13][14][15] The limitation of this study is that the subjects were only parents of young children (1-5 years) with PIDD. Parents with infants or young children with PIDD would always be more worried about the diseases and infections.…”

Section: Discussionmentioning

confidence: 99%

“…In our study, parents who preferred SCIg for their children were primarily guided by the smaller number of side effects. Several clinical trials of subcutaneously administered infusions of immunoglobulin, formulated for intramuscular use, provided high serum levels for IgG and comparable protection from infection, while adverse events were reduced when compared to IVIg …”

Section: Discussionmentioning

confidence: 99%

“…Both IVIg and SCIg replacement therapies affect patients’ quality of life . In our previous study, we found that SCIg therapy was much more effective and safe than IVIg for children with PIDD, and that it should be given as early as possible to decrease the number of hospitalizations …”

mentioning

confidence: 99%

“…5 In our previous study, we found that SCIg therapy was much more effective and safe than IVIg for children with PIDD, and that it should be given as early as possible to decrease the number of hospitalizations. 6 The aim of the present study was to determine the advantages and disadvantages of hospital-based intravenous immunoglobulin (IVIg) and home-based self-administered immunoglobin (SCIg) in young Polish children with primary immunodeficiency diseases, and the satisfaction of their parents / caregivers regarding immunoglobulin replacement.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The influence of hospital‐based intravenous immunoglobulin and home‐based self‐administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents’ / caregivers’ satisfaction

Lechanska‐Helman

Sobocińska

Jerzyńska

et al. 2020

Pediatrics International

Self Cite

View full text Add to dashboard Cite

Background Immunoglobulin replacement has been standard therapy for patients with primary immunodeficiency diseases (PIDD). Intravenous immunoglobin (IVIg) is delivered at the hospital, whereas subcutaneous immunoglobin (SCIg) is used for home‐based treatment. The aim of the study was to determine the advantages and disadvantages of IVIg and SCIg in Polish children aged 1–5 years, with PIDD, and the satisfaction of their parents / caregivers regarding immunoglobulin replacement. Methods The research involved parents of 23 children with PIDD, aged 1–5 years. All children were given IVIg therapy and after at least 6 months they were switched towards home SCIg therapy for at least 6 months. A questionnaire assessing advantages and disadvantages of preferred types of treatment and the quality of life of PIDD patients’ families’ lives was used. Results The research showed that IVIg therapy was better accepted by parents than SCIg therapy (P = 0.034) for the following reasons: It made it possible for the children to receive treatment once per month (60%); it reduced the fear of injecting the children (60%), and it provided better control of the disease through regular visits to the hospital (53.33%). Parents noticed, however, that IVIg had a significant impact on absence at school or work (70%). Parents who preferred SCIg for their children were guided mainly by the smaller number of side effects (40%), and the fact that the treatment did not interfere with parents’ work or the children’s school (40%). Conclusion The results showed that IVIg therapy was better accepted by parents than SCIg therapy Parents of children with SCIg are less satisfied with their life, and feel anxiety about their children disease, which is related to administering the medicine by themselves.

show abstract

Parenteral Therapy in Domiciliary and Outpatient Setting: A Critical Review of the Literature

Puzovic¹,

Morrissey²,

Ball³

2023

Arch Pharm Pract

View full text Add to dashboard Cite

The clinical homecare sector is often associated with high-cost drug parenteral (injectable) therapy treatments and has been rapidly growing in the United Kingdom (UK) at a 20% annual rate. It was estimated that this could further rise to 60% if extended to all medicines that are considered to be suitable for care at home. The latest data shows that the homecare medicines services sector continues to grow in number and complexity, with over 500,000 patients and a spend of UK£3.2 billion in 2021. Given the extent of the National Health Service (NHS) expenditure and the number of patients involved, it is essential to understand and explore the patients' and HCPs' experiences, views, and perceptions of this therapy. As identified during this literature review, homecare provides opportunities for improved cost savings and improved patient experience, but several issues have already been reported worldwide. Patient education, training, support, and regular supervision, as well as the competency of HCPs to manage these patients, have all been identified as factors that contribute to the success or failure of self-administration of parenteral therapy at home, which might impact treatment outcomes and adherence. This is an area that needs urgent research.

show abstract

Efficacy and Safety of Hospital-Based Intravenous Immunoglobulin and Home-Based Self-Administered Subcutaneous Immunoglobulin in Polish Children with Primary Immunodeficiency Diseases

Cited by 3 publications

References 5 publications

Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease

Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease

The influence of hospital‐based intravenous immunoglobulin and home‐based self‐administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents’ / caregivers’ satisfaction

Parenteral Therapy in Domiciliary and Outpatient Setting: A Critical Review of the Literature

Contact Info

Product

Resources

About